Answer a short survey to help the ACR’s Committee on Rheumatologic Care decide whether the ACR should seek CMS approval for synovial fluid crystal analysis as a provider-performed microscopy procedure.
State Legislative Update, Spring 2025
With the state legislative session in full swing, the ACR is currently tracking 114 pieces of state legislation across many issue areas, including utilization management, prescription drug review boards and vaccines.
CMS Nominee Mehmet Oz’s Stated Policy Priorities & Rheumatology
With Mehmet Oz, MD, expected to be confirmed as administrator of the Centers for Medicare & Medicaid Services, the ACR considers how his stated priorities may affect rheumatology.
ACR Commends the Introduction of Legislation to Support the Medical Workforce
Three bills centering reintroduced in the 119th Congress would ease educational debt burden, increase placement access for visa holders and support the mental health of current healthcare workers.
March Updates from the ACR Insurance Subcommittee
The Insurance Subcommittee is working on behalf of ACR members to address underwater formulary requirements for biosimilars, mandated switches to biosimilars, evaluation and management downcoding and more.
Legal Updates: Compliance Planning for Your Practice
Physicians have a lot going on. Between the pressures of clinical and administrative responsibilities, sometimes the only way to keep everything together is with a to-do list. Unfortunately, it can often feel as though some items never come off that list. Often, the bigger a project sounds, the more likely it is to sit on…
Rheum for Everyone, Episode 18: ‘COVID in the Rear View’ (video)
In this episode of his monthly video series for The Rheumatologist, physician editor Dr. Bharat Kumar talks about isolation and its impact on our patients with rheumatic disease, and the rheumatologist’s role in combating it.
Rheum With a (re)View
Here participants in the ACR’s Rheum With a (re)View program discuss how its mentors provided them with skills and knowledge that benefit their careers and rheumatology as a community.
HHS Policy Shift Raises Questions about Future of Public Comment on Rulemaking
The rescindment of the Richardson Waiver in late February suggests that the HHS may move toward rulemaking without providing public notice and comment procedures.
How NIH, FDA Nominees May Affect Rheumatology
The nominations of Jay Bhattacharya, MD, PhD, as director of the National Institutes of Health and Martin Makary, MD, MPH, for commissioner of the Food & Drug Administration have the potential to significantly impact federally funded healthcare research, federal responses to public health emergencies and federal regulation of drugs and medical devices.
- « Previous Page
- 1
- 2
- 3
- 4
- 5
- …
- 814
- Next Page »